777 replies to this topic

[ImmInst]

Company Shares of BioTime, Inc. (NYSEMKT:BTX) Drops by -2.23%
OTC Outlook - 4 hours ago

BioTime, Inc. (NYSEMKT:BTX) has dropped 2.23% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 13.64% in the last 4 weeks.

View the full article

[ImmInst]

Form 8-K BIOTIME INC For: Sep 25
StreetInsider.com - 1 hour ago

Any statements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,” “believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking ...

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track ... - PharmiWeb.com (press release)
BioTime Subsidiary Cell Cure Receives FDA Fast-Track Status For OpRegen - RTT News

View the full article

[ImmInst]

Stocks With Sudden Spurt In Volumes:Bellerophon Therapeutics Inc (NASDAQ:BLPH ...
Wall Street Point - 1 hour ago

BioTime, Inc.(NYSEMKT:BTX) recently exchanged hands on above-normal volume of 1.10Millionshares compared with average daily volume of 284,822shares.

Investors Alert: Verastem Inc(NASDAQ:VSTM), BioTime, Inc. (NYSEMKT:BTX ... - Market News Call

View the full article

[ImmInst]

Stocks Preparing To Gain Concentrations- BioTime, Inc. (NYSEMKT:BTX), Alnylam ...
StreetWise Report - 2 hours ago

BioTime, Inc. (NYSEMKT:BTX) hit high price of $3.20 to close at $2.94 by decreasing -16.00% with session volume was recorded 1.1 Million.

Stocks in Hot Move: BioTime, Inc. (NYSEMKT:BTX), Whole Foods Market, Inc ... - eMarketsDaily

View the full article

[ImmInst]

Form 8-K BIOTIME INC For: Sep 29
StreetInsider.com - 7 hours ago

Any statements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,” “believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking ...

Heraeus Medical GmbH and BioTime Subsidiary OrthoCyte Corporation Enter Into ... - Business Wire (press release)

View the full article

[ImmInst]

Recent Percent Declines Stocks: BioTime, Inc (NYSEMKT: BTX), La Jolla ...
Economic News Daily - 13 hours ago

BioTime, Inc (NYSEMKT: BTX) ended last trading session with a change of -1.02 percent. It trades at an average volume of 284.90K shares versus 504983 shares recorded at the end of last trading session.

View the full article

[ImmInst]

BioTime Announces the Closing of a $20 Million Direct Registered Offering ...
Business Wire (press release) - 16 hours ago

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that BioTime completed a registered direct offering of ...

View the full article

[ImmInst]

BioTime, Inc. Agrees to Sell $5.1 Million of Equity
Business Wire (press release) - 2 hours ago

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it has agreed to sell 1,600,000 of its common shares, ...

View the full article

[ImmInst]

Company Shares of BioTime, Inc. (NYSEMKT:BTX) Rally 5.43%
Insider Trading Report - 4 hours ago

Shares of BioTime, Inc. (NYSEMKT:BTX) rose by 5.43% in the past week and 14.6% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 4.35% and the outperformance increases to 12.83% for the last 4 weeks.

5 Stocks Under Wall Street's Radar: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ... - Benchmark Monitor

View the full article

[ImmInst]

BioTime's Subsidiary OncoCyte Corporation Files Form 10 Registration Statement ...
Business Wire (press release) - 15 hours ago

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, and its subsidiary OncoCyte Corporation (“OncoCyte”), today announced that ...

View the full article

[ImmInst]

Company Shares of BioTime, Inc. (NYSEMKT:BTX) Drops by -7.59%
Insider Trading Report - 9 hours ago

BioTime, Inc. (NYSEMKT:BTX) has dropped 7.59% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 3.65% in the last 4 weeks.

View the full article

[ImmInst]

BioTime Inc.: Asterias Biotherapeutics Announces Collaboration with Cell ...
The Wall Street Transcript - 14 hours ago

MENLO PARK, Calif., Oct. 13, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), has signed an agreement with the UK-based Cell Therapy Catapult to advance development of large scale manufacturing processes for AST-VAC2, ...

Asterias signs agreement with Cell Therapy Catapult; will establish in UK - The Pharma Letter (registration)

View the full article

[ImmInst]

Biotech Stocks News Update- BioTime, Inc. (NYSEMKT:BTX), Pacific Biosciences ...
Investor Wired - 1 hour ago

BioTime, Inc. (NYSEMKT:BTX) increased 4.39% and closed at $3.57 in the last trading session with the overall traded volume of 865,492 shares, versus the average volume of 342,066 shares.

View the full article

[ImmInst]

BioTime Inc. (BTX) Jumps 6.16% on October 14
Equities.com - 14 hours ago

BioTime Inc. (BTX) was among the biggest gainers on the Russell 2000 for Wednesday October 14 as the stock popped 6.16% to $3.79, representing a gain of $0.22 per share.

View the full article

[ImmInst]

Big Movers: BioTime, Inc. (NYSEMKT:BTX), Bloomin' Brands, Inc. (NASDAQ:BLMN ...
Benchmark Monitor - 1 hour ago

BioTime, Inc. (NYSEMKT:BTX) on Oct 07, announced that OncoCyte has filed a Form 10 Registration Statement with the Securities and Exchange Commission (“SEC”) in connection with BioTime's planned distribution OncoCyte common stock to holders of ...

View the full article

[ImmInst]

Company Shares of BioTime, Inc. (NYSEMKT:BTX) Rally 13.49%
Insider Trading Report - 3 hours ago

Shares of BioTime, Inc. (NYSEMKT:BTX) rose by 13.49% in the past week and 8.1% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 12.47% and the outperformance increases to 4.11% for the last 4 weeks.

View the full article

[ImmInst]

Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime, Inc.
Business Wire (press release) - 3 hours ago

BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, reported today that its Board of Directors has appointed Adi Mohanty to serve with Michael D.

View the full article

[ImmInst]

Form 8-K BIOTIME INC For: Oct 12
StreetInsider.com - 7 hours ago

Any statements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,” “believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking ...

Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime, Inc. - Business Wire (press release)

View the full article

[ImmInst]

BioTime, Inc. on Focus After Raisting In Today's Session
FinancialMagazin.com - 3 hours ago

The stock of BioTime, Inc. (BTX) is a huge mover today! The stock increased 4.13% or $0.16 during the last trading session, hitting $4.03.

View the full article

[ImmInst]

Company Shares of BioTime, Inc. (NYSEMKT:BTX) Rally 2.84%
American Trade Journal - 1 hour ago

Shares of BioTime, Inc. (NYSEMKT:BTX) rose by 2.84% in the past week and 13.71% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 0.76% and the outperformance increases to 5.83% for the last 4 weeks.

View the full article

[ImmInst]

Company Shares of BioTime, Inc. (NYSEMKT:BTX) Rally 2.84%
American Trade Journal - 4 hours ago

Shares of BioTime, Inc. (NYSEMKT:BTX) rose by 2.84% in the past week and 13.71% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 0.76% and the outperformance increases to 5.83% for the last 4 weeks.

View the full article

[ImmInst]

Short Interest Update on BioTime, Inc.
Insider Trading Report - 2 hours ago

BioTime, Inc. (NYSEMKT:BTX) has shown a drop of 11.3% or 890,165 shares in the short positions. The bets have increased to 7,012,038 shares on October 15,2015 from 7,902,203 shares on September 30,2015.

View the full article

[ImmInst]

Company Shares of BioTime, Inc. (NYSEMKT:BTX) Drops by -5.28%
American Trade Journal - 4 hours ago

BioTime, Inc. (NYSEMKT:BTX) has dropped 5.28% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 2.17% in the last 4 weeks.

View the full article

[ImmInst]

BioTime Inc.: LifeMap Sciences, a Subsidiary of BioTime, and Lab7 Systems ...
The Wall Street Transcript - 38 minutes ago

AUSTIN, Tex., November 4, 2015 - LifeMap Sciences, Inc. ('LifeMap'), a subsidiary of BioTime, Inc., and Lab7 Systems, Inc., announced today a partnership and launch of an integrated solution in the next-generation genomic sequencing (NGS) field, ...

LifeMap Sciences, a Subsidiary of BioTime, and Lab7 Systems Announce ... - Business Wire (press release)

View the full article

[ImmInst]

BioTime, Inc. and Hepregen Corporation Form Ascendance Biotechnology, Inc. to ...
Business Wire (press release) - 27 minutes ago

ALAMEDA, Calif. & MEDFORD, Mass.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company, and Hepregen Corporation, a privately held company engaged in the development and marketing of ...

View the full article

[ImmInst]

Analysis and BioTime, Inc. (BTX) Earnings Review
FinancialMagazin.com - 34 minutes ago

Investors wait BioTime, Inc. (NYSEMKT:BTX) to report on November, 9. its quarterly earnings The stock increased 0.26% or $0.01 on November 6, hitting $3.84.

View the full article

[ImmInst]

BioTime, Inc. Reports Third Quarter 2015 Results and Recent Corporate ...
Business Wire (press release) - 1 hour ago

On November 5, 2015, BioTime and Hepregen Corporation formed Ascendance Biotechnology, Inc., a new self-funding company that combines Hepregen's cellular micro-patterning drug and chemical screening technologies with BioTime's ESI-BIO research ...

View the full article

[ImmInst]

BioTime Inc.: Asterias Biotherapeutics Reports Third Quarter Results
The Wall Street Transcript - 53 minutes ago

9, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today reported financial and operating results for the third quarter ended September 30, 2015.

View the full article

[ImmInst]

Insider Deal: Stephen Farrell Obtained 50000 Shares of BioTime, Inc. (NYSEMKT:BTX)
FinancialMagazin.com - 2 hours ago

Mr. Stephen Farrell, the key director at Biotime Inc has not a long ago been linked with a trade of 50,000 shares of the Amex-listed company, valued at $3.8 per share .

View the full article

[ImmInst]

What's Ahead for BioTime, Inc. After Today's Huge Decline?
FinancialMagazin.com - Nov 10, 2015

The stock of BioTime, Inc. (BTX) is a huge mover today! The stock decreased 7.55% or $0.29 during the last trading session, hitting $3.55.

View the full article